During a recent interview at a Las Vegas event, Elon Musk confirmed that a third individual has received an implant from his brain-computer interface company Neuralink. Musk stated that all three recipients are doing well since the implantation, and the devices have been upgraded with more electrodes, higher bandwidth, and improved battery life compared to the initial version implanted a year ago. Neuralink aims to implant these experimental devices in 20 to 30 more individuals within the year.
While specifics about the latest recipient were not provided, previous patients have reported positive outcomes. For instance, the second recipient, who suffered a spinal cord injury, was able to play video games and learn computer-aided design software thanks to the device. The first patient, also paralyzed due to a spinal cord injury, found assistance in gaming and chess through the implant.
Although Neuralink’s advancements garner significant attention, numerous other companies and research organizations are also exploring brain-computer interface (BCI) technology. More than 45 trials are currently in progress to develop BCIs for various applications, such as treating brain disorders and enhancing brain injury recovery.
Rajesh Rao from the University of Washington highlighted that Neuralink’s approach, particularly the use of a robot to implant flexible electrode threads for neural activity recording, may set it apart from competitors. However, the effectiveness of Neuralink’s method remains to be demonstrated, with other companies like Synchron and Blackrock Neurotech employing different, potentially more versatile, approaches in BCI development.
BCIs offer promising benefits to individuals with paralysis, according to Marco Baptista from the Christopher & Dana Reeve Foundation. Baptista emphasized the importance of supporting research endeavors, acknowledging the risks and rewards associated with BCI technology.
As for regulatory aspects, Neuralink announced receiving approval from U.S. regulators to conduct testing on its devices in 2023. While most medical devices can enter the market without extensive clinical studies, high-risk devices require regulatory clearances such as an “investigational device exemption” from the Food and Drug Administration (FDA).
The Food and Drug Administration, as stated by Dr. Rita Redberg, a cardiologist at the University of California, San Francisco, specializing in the study of high-risk medical devices. Neuralink claims to possess an exemption; however, the FDA has mentioned that it is unable to verify or disclose information regarding a specific study. Dr. Redberg highlighted that the FDA typically plays a role in every stage of the process, from patient recruitment to device testing and data analysis. She emphasized that this regulatory procedure places a strong emphasis on ensuring safety.
Furthermore, Dr. Redberg noted an additional layer of safeguarding measures: Any research involving human subjects must be reviewed by an institutional review board (IRB), also referred to as an ethical review board or an independent ethics committee. IRB members are required to include at least one individual who is not a scientist and someone who is not associated with the institution or organization overseeing the board. Dr. Redberg explained that the primary responsibility of these boards is to operate under the assumption that there is a reasonable level of risk and potential benefit, ensuring that patients are fully informed before consenting to participate.
The Associated Press Health and Science Department is supported by the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP retains full editorial control and responsibility for all content published.
